• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

48.81 -0.19 (-0.38%)
Streaming Delayed Price Updated: 1:52 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform ↗
August 16, 2026
Pulse Biosciences (NASDAQ:PLSE) is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President,... 
Via MarketBeat
Topics Intellectual Property
News headline image
Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
NANOPULSE-AF enrollment hit halfway point ahead of schedule with 82 patients. 
Via The Motley Fool
Topics Earnings
News headline image
Pulse Biosciences Q2 Earnings Call Highlights ↗
August 07, 2026
Pulse Biosciences (NASDAQ:PLSE) reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
August 06, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
July 30, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
July 29, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
July 21, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 15, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
June 10, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
May 27, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. ↗
May 17, 2026
Pulse Biosciences, a developer of non-thermal bioelectric treatments, reported a notable insider buy amid recent stock price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
May 12, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Q1 Earnings Call Highlights ↗
May 08, 2026
Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new... 
Via MarketBeat
Topics Earnings
News headline image
PLSE Q1 2026 Earnings Transcript ↗
May 08, 2026
PLSE Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
May 08, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript ↗
May 04, 2026
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
PLSE Q4 2025 Earnings Transcript ↗
May 04, 2026
PLSE Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
May 04, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
April 25, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
April 20, 2026
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences to Host Analyst Event on April 25, 2026
April 17, 2026
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences Strengthens Executive Leadership Team
April 09, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
April 07, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
April 02, 2026
From Pulse Biosciences, Inc
Via Business Wire
News headline image
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
March 17, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
March 12, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
March 09, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
March 05, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
March 04, 2026
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap